Q2 2026 saw 22% revenue growth to $382.5M, a swing to $5.6M net income, and strong gains in Diagnostics and Data & Applications. Guidance calls for 25% full-year revenue growth and positive cash flow by year-end, with the Personalis acquisition set to expand MRD capabilities.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.